title: Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial.
abstract: OBJECTIVE
  The aim of this analysis was to compare the long-term safety and efficacy of the biodegradable polymer biolimus-eluting stent (BES) with that of the durable polymer everolimus-eluting stent (EES).
  
  
  RESULTS
  The COMPARE II study was a prospective, randomised, multicentre, all-comers trial in which 2,707 patients were randomly allocated (2:1) to BES or EES. The pre-specified endpoint at three years was major adverse cardiac events (MACE), a composite of cardiac death, non-fatal myocardial infarction (MI), or target vessel revascularisation (TVR). Moreover, the combined endpoint all-cause death or MI was analysed as a safety, and TVR as an efficacy measure. Three-year follow-up was available in 2,683 patients (99.1%). At three years, MACE occurred in 213 patients (11.9%) in the BES group and in 101 patients (11.1 %) in the EES group (p=0.57). The rate of the combined safety endpoint all-cause death or MI was 9.3% in the BES group vs. 8.4% (p=0.52), while the efficacy measure TVR was 7.6% in BES vs. 6.5% (p=0.27). Interestingly, definite stent thrombosis rates did not differ between groups (1.2% for BES vs. 0.8%, p=0.33).
  
  
  CONCLUSIONS
  At three-year follow-up, MACE as well as safety and efficacy measures including stent thrombosis were not statistically different between the biodegradable polymer-coated BES and the durable polymer-coated EES. ClinicalTrials.gov Identifier: NCT01233453.
authors.affiliation: Department of Cardiology, Maasstad Hospital, Rotterdam, The Netherlands.
authors.forename: Georgios J
authors.initials: GJ
authors.lastname: Vlachojannis
authors.forename: Pieter C
authors.initials: PC
authors.lastname: Smits
authors.forename: Sjoerd H
authors.initials: SH
authors.lastname: Hofma
authors.forename: Mario
authors.initials: M
authors.lastname: Togni
authors.forename: Nicolás
authors.initials: N
authors.lastname: Vázquez
authors.forename: Mariano
authors.initials: M
authors.lastname: Valdés
authors.forename: Vassilis
authors.initials: V
authors.lastname: Voudris
authors.forename: Serban
authors.initials: S
authors.lastname: Puricel
authors.forename: Ton
authors.initials: T
authors.lastname: Slagboom
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Goy
authors.forename: Peter
authors.initials: P
authors.lastname: den Heijer
authors.forename: Martin
authors.initials: M
authors.lastname: van der Ent
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D003324:Coronary Artery Disease / Q000601:surgery*; D003328:Coronary Thrombosis / Q000453:epidemiology; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000737:chemistry / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D011108:Polymers / Q000737:chemistry; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D000068338:Everolimus